Medical School · Year 1 · Foundations · includes a quiz and discussion video

Lecture 7: Oxidative Phosphorylation

Unit 1.1: Foundations of Medicine & Medical Sciences

Learning Objectives

By the end of this lecture, students will be able to:

1. Describe the components and organization of the electron transport chain (Complexes I-IV)
2. Explain the chemiosmotic theory and the mechanism of ATP synthesis by ATP synthase
3. Calculate the theoretical ATP yield from the complete oxidation of glucose
4. Identify common inhibitors and uncouplers of oxidative phosphorylation and their mechanisms
5. Describe the role of mitochondrial shuttle systems in transporting cytoplasmic NADH
6. Explain the clinical significance of mitochondrial disorders and oxidative phosphorylation defects

Lecture Content

I. Introduction to Oxidative Phosphorylation

Oxidative phosphorylation represents the culmination of aerobic respiration—the process by which cells extract the maximum possible energy from fuel molecules. While glycolysis and the TCA cycle generate only modest amounts of ATP directly, they produce abundant NADH and FADH₂, reduced coenzymes carrying high-energy electrons. Oxidative phosphorylation harnesses the energy released when these electrons are transferred to oxygen, using it to synthesize the vast majority of cellular ATP. This process accounts for approximately 90% of ATP production in aerobic cells.

The process takes place at the inner mitochondrial membrane, where a series of protein complexes collectively known as the electron transport chain (ETC) passes electrons from NADH and FADH₂ to molecular oxygen. The energy released during this electron transfer is not captured directly as ATP; rather, it drives the pumping of protons (H⁺) across the inner membrane from the matrix to the intermembrane space. This proton gradient stores potential energy that is subsequently released as protons flow back through ATP synthase, driving the synthesis of ATP from ADP and inorganic phosphate.

The overall process thus couples oxidation (electron transfer to oxygen) with phosphorylation (ATP synthesis)—hence the name oxidative phosphorylation. Oxygen serves as the final electron acceptor, being reduced to water. Without oxygen, the electron transport chain halts, the proton gradient dissipates, and ATP synthesis by this pathway ceases—explaining why oxygen is essential for aerobic life.

<image>Panel A: Inner mitochondrial membrane cross-section with matrix (blue, pH ~8) below and intermembrane space (pink, pH ~7) above showing Complexes I-II. Panel B: Complexes III-IV with mobile carriers CoQ (yellow) shuttling between I/II and III, cytochrome c (orange) between III and IV. Panel C: Red arrows showing electron flow from NADH to O2→H2O with blue arrows indicating proton pumping at Complexes I, III, IV. Panel D: ATP synthase (gold mushroom shape) with protons flowing through generating ATP and dense H+ gradient visualization.</image>

II. Mitochondrial Structure Review

Understanding oxidative phosphorylation requires appreciation of mitochondrial architecture, particularly the specialized properties of the inner membrane.

The outer mitochondrial membrane is relatively permeable, containing porin proteins that allow free passage of molecules up to approximately 5 kilodaltons. This membrane separates the mitochondrion from the cytoplasm but does not present a significant barrier to small metabolites.

The intermembrane space, lying between the outer and inner membranes, has a composition similar to the cytoplasm because of the outer membrane's permeability. This compartment accumulates protons pumped from the matrix during electron transport, giving it a lower pH and positive electrical charge relative to the matrix. The small, soluble protein cytochrome c resides in this space, shuttling electrons between Complexes III and IV.

The inner mitochondrial membrane is the site of oxidative phosphorylation and possesses distinctive features suited to this function. Unlike most cellular membranes, it is highly impermeable—specific transport proteins control virtually all traffic across it. This impermeability is essential for maintaining the proton gradient that drives ATP synthesis. The membrane is extensively folded into cristae, dramatically increasing its surface area to accommodate abundant electron transport chain complexes and ATP synthase molecules. The high protein-to-lipid ratio reflects the membrane's functional specialization, with the respiratory complexes and ATP synthase constituting a large fraction of its mass.

The matrix, enclosed by the inner membrane, contains the enzymes of the TCA cycle and fatty acid β-oxidation—the pathways that generate the NADH and FADH₂ feeding the electron transport chain. The matrix also houses mitochondrial DNA and ribosomes, reflecting the organelle's evolutionary origin as an endosymbiotic bacterium.

III. The Electron Transport Chain

The electron transport chain comprises four multiprotein complexes embedded in the inner mitochondrial membrane, plus two mobile carriers that shuttle electrons between complexes. Electrons enter the chain from NADH (at Complex I) or FADH₂ (at Complex II) and are passed through progressively more electronegative carriers until they reduce oxygen to water at Complex IV.

Complex I: NADH Dehydrogenase

Complex I, also known as NADH-ubiquinone oxidoreductase, is the largest of the respiratory complexes—a massive L-shaped structure containing over 40 subunits. It accepts electrons from NADH, the primary electron donor from glycolysis, pyruvate dehydrogenase, and the TCA cycle. The reaction can be summarized as: NADH + H⁺ + CoQ → NAD⁺ + CoQH₂.

Electrons from NADH are first transferred to a flavin mononucleotide (FMN) prosthetic group, then passed through a series of iron-sulfur clusters before reducing ubiquinone (coenzyme Q) to ubiquinol. The energy released during this electron transfer drives the pumping of four protons from the matrix to the intermembrane space. Several clinically relevant inhibitors block Complex I: rotenone (a pesticide), certain barbiturates, and MPP⁺ (a neurotoxin that causes parkinsonism in drug users exposed to MPTP-contaminated heroin).

Complex II: Succinate Dehydrogenase

Complex II has the unique distinction of participating in both the TCA cycle and the electron transport chain—it is the succinate dehydrogenase enzyme that catalyzes the oxidation of succinate to fumarate (TCA cycle step 6). The FADH₂ generated remains bound to the enzyme and directly transfers electrons to ubiquinone: Succinate + CoQ → Fumarate + CoQH₂.

Unlike the other proton-pumping complexes, Complex II does not pump protons across the inner membrane. This explains why FADH₂ yields fewer ATP molecules than NADH—electrons from FADH₂ bypass Complex I and its associated proton pumping. Malonate, a structural analog of succinate, competitively inhibits Complex II.

Ubiquinone (Coenzyme Q)

Ubiquinone is a lipid-soluble mobile carrier that diffuses freely within the inner mitochondrial membrane. It collects electrons from both Complex I and Complex II and delivers them to Complex III. Because it can accept one or two electrons, ubiquinone can participate in both one-electron and two-electron transfer reactions. The reduced form, ubiquinol (CoQH₂), carries both electrons and protons.

<image>Panel A: Complex I L-shaped structure with membrane arm horizontal and matrix arm extending down, NADH binding site at tip with FMN (yellow) receiving electrons. Panel B: Complex I iron-sulfur cluster chain (brown/yellow cubes) extending to ubiquinone binding site with four proton channels showing H+ pumping. Panel C: Complex II membrane-embedded with FAD (yellow) showing succinate entry, fumarate exit, and electrons via Fe-S clusters to CoQ with "No proton pumping" label. Panel D: Ubiquinone molecules (orange-yellow circles with tails) accepting electrons from both complexes moving toward Complex III.</image>

Complex III: Cytochrome bc₁ Complex

Complex III, also called ubiquinol-cytochrome c oxidoreductase, accepts electrons from ubiquinol and transfers them to cytochrome c. This complex employs a sophisticated mechanism called the Q cycle that effectively doubles the proton-pumping efficiency. The prosthetic groups include heme b and heme c₁ (containing iron) and an iron-sulfur cluster known as the Rieske protein.

For each pair of electrons passing through Complex III, four protons are pumped across the membrane. The antibiotic antimycin A specifically inhibits Complex III. The overall reaction transfers electrons from ubiquinol (a two-electron carrier) to cytochrome c (a one-electron carrier): CoQH₂ + 2 Cyt c (Fe³⁺) → CoQ + 2 Cyt c (Fe²⁺) + 2 H⁺.

Cytochrome c

Cytochrome c is a small, soluble protein that resides in the intermembrane space and shuttles electrons one at a time from Complex III to Complex IV. Its heme group alternates between ferric (Fe³⁺) and ferrous (Fe²⁺) states as it picks up and delivers electrons. Beyond its role in respiration, cytochrome c plays a critical role in apoptosis: when released from mitochondria into the cytoplasm, it triggers the caspase cascade that executes programmed cell death.

Complex IV: Cytochrome c Oxidase

Complex IV, cytochrome c oxidase, catalyzes the final step of the electron transport chain—the four-electron reduction of molecular oxygen to water: 4 Cyt c (Fe²⁺) + O₂ + 8 H⁺ → 4 Cyt c (Fe³⁺) + 2 H₂O + 4 H⁺ (pumped).

The complex contains copper centers (Cu_A and Cu_B) in addition to heme groups (heme a and heme a₃). These metal centers hold oxygen in place while it receives four electrons, preventing the release of partially reduced oxygen species that would damage the cell. Two protons are pumped for each pair of electrons traversing Complex IV.

Complex IV inhibitors are among the most acutely toxic substances known. Cyanide (CN⁻) and azide (N₃⁻) bind tightly to the heme iron in its ferric state, blocking oxygen binding. Carbon monoxide (CO) binds preferentially to the reduced (ferrous) heme. All these inhibitors cause histotoxic hypoxia—cells have oxygen but cannot use it, halting all aerobic ATP production.

<image>Panel A: Complex I (blue) with NADH entering, electrons through FMN and Fe-S to CoQ, 4 H+ pumped; Complex II (green) with succinate, no proton pumping (X). Panel B: Ubiquinone pool (yellow) connecting to Complex III (purple) showing Q cycle components pumping 4 H+. Panel C: Cytochrome c (orange) shuttling to Complex IV (red) with Cu and heme centers, O2 to H2O, 2 H+ pumped per electron pair. Panel D: Summary showing 10 H+/NADH and 6 H+/FADH2 with inhibitor labels: rotenone, malonate, antimycin A, cyanide/CO at respective sites.</image>

IV. Proton Gradient and Chemiosmotic Theory

The proton gradient generated by the electron transport chain represents stored potential energy that drives ATP synthesis. Peter Mitchell proposed this chemiosmotic theory in 1961, initially meeting considerable skepticism but ultimately earning the Nobel Prize in Chemistry in 1978 as evidence accumulated in its favor.

The Proton-Motive Force

The proton-motive force (Δp) comprises two components that together represent the total energy stored in the proton gradient. The chemical component (ΔpH) reflects the concentration gradient—protons are more concentrated in the intermembrane space (lower pH, around 7) than in the matrix (higher pH, around 8). The electrical component (Δψ) reflects the charge separation—the intermembrane space is positively charged relative to the negatively charged matrix. The proton-motive force is typically around 180-220 mV, with the electrical component (Δψ ≈ 140-180 mV) contributing more than the chemical component.

Proton Pumping Stoichiometry

The number of protons pumped differs depending on where electrons enter the chain. Electrons from NADH enter at Complex I, traversing the full chain and driving proton pumping at Complexes I, III, and IV: 4 + 4 + 2 = 10 protons per NADH. Electrons from FADH₂ enter at Complex II, which does not pump protons, so they drive pumping only at Complexes III and IV: 4 + 2 = 6 protons per FADH₂.

This difference in proton yield explains why NADH generates approximately 2.5 ATP while FADH₂ generates only 1.5 ATP—the lesser proton gradient from FADH₂ drives less ATP synthesis.

<image>Panel A: Inner membrane cross-section with intermembrane space (light red, dense H+, pH ~7, positive) and matrix (light blue, sparse H+, pH ~8, negative). Panel B: Proton-motive force gauges showing deltapH (~0.5-1 unit) and deltaPsi (~140-180 mV) summing to ~200 mV total. Panel C: Arrows showing proton flow tendency toward matrix (chemical and electrical driving forces) with Peter Mitchell Nobel Prize 1978 inset. Panel D: Proton pumping comparison table: NADH pathway 10 H+ yielding ~2.5 ATP, FADH2 pathway 6 H+ yielding ~1.5 ATP.</image>

V. ATP Synthase (Complex V)

ATP synthase is a remarkable molecular machine that converts the energy stored in the proton gradient into the chemical energy of ATP. Its mechanism, elucidated primarily by Paul Boyer (Nobel Prize 1997), reveals it to be a rotary motor—one of the smallest known.

Structure

ATP synthase consists of two main portions: the F₀ portion embedded in the inner membrane and the F₁ portion projecting into the matrix where ATP synthesis occurs.

The F₀ portion forms a proton channel and includes the c-ring—a ring of 8-15 c subunits (the number varies between species) that rotates as protons flow through the complex. The a subunit provides the channel that allows protons to access the c-ring from the intermembrane space and exit to the matrix.

The F₁ portion contains the catalytic machinery. It consists of a hexameric ring of alternating α and β subunits (α₃β₃), with the three β subunits containing the active sites for ATP synthesis. The central stalk (γ, δ, and ε subunits) connects F₁ to the rotating c-ring of F₀, transmitting the rotational motion.

The Binding Change Mechanism

Proton flow through F₀ drives rotation of the c-ring and the attached central stalk (γ subunit). This rotation within the stationary α₃β₃ hexamer induces sequential conformational changes in the three β subunits, which cycle through three states:

The Open (O) state has low affinity for substrates and products, allowing ATP release and binding of ADP and inorganic phosphate. The Loose (L) state binds ADP and phosphate but does not catalyze synthesis. The Tight (T) state catalyzes the formation of ATP from ADP and phosphate—remarkably, this step requires essentially no energy input; the energy is instead used to release the tightly bound ATP in the subsequent conformational change to the O state.

Each 360° rotation of the γ subunit produces three ATP molecules, one from each β subunit. Approximately 3-4 protons must flow through F₀ to drive the conformational changes that synthesize and release one ATP. An additional proton is effectively consumed in transporting ATP out of the matrix and ADP plus phosphate in, bringing the total to about 4 protons per ATP.

<image>Panel A: F0 portion embedded in membrane showing c-ring (light blue, 10 subunits with rotation arrow) and a subunit (dark blue) with proton half-channels. Panel B: Central stalk (gamma yellow, epsilon orange, delta) linking c-ring to F1 with protons entering from intermembrane space and exiting to matrix. Panel C: F1 portion alpha3beta3 hexamer with beta subunits in three conformational states: O (Open, ATP leaving), L (Loose, ADP+Pi bound), T (Tight, ATP forming). Panel D: 360-degree rotation producing 3 ATP molecules with ~4 H+ per ATP equation.</image>

VI. Complete ATP Yield from Glucose

The complete aerobic oxidation of one glucose molecule can be summarized by tallying the reduced coenzymes produced at each stage and converting them to ATP equivalents.

Glycolysis, occurring in the cytoplasm, produces 2 ATP directly (net) and 2 NADH. The pyruvate dehydrogenase reaction, converting two pyruvates to two acetyl-CoA molecules, produces 2 NADH. Two turns of the TCA cycle (one per acetyl-CoA) produce 6 NADH, 2 FADH₂, and 2 GTP (equivalent to 2 ATP).

The total is therefore 4 ATP produced directly, plus 10 NADH and 2 FADH₂. Converting the reduced coenzymes to ATP via oxidative phosphorylation: 10 NADH × 2.5 ATP = 25 ATP, and 2 FADH₂ × 1.5 ATP = 3 ATP. The grand total is 4 + 25 + 3 = 32 ATP.

However, the 2 NADH from glycolysis are produced in the cytoplasm, where NADH cannot directly enter the mitochondria. The ATP yield from these depends on which shuttle system transports their electrons into the matrix. The malate-aspartate shuttle preserves the electrons at the NADH level, yielding 2.5 ATP per cytoplasmic NADH (total: 32 ATP per glucose). The glycerol-3-phosphate shuttle transfers electrons to FAD rather than NAD⁺, yielding only 1.5 ATP per cytoplasmic NADH (total: 30 ATP per glucose).

Different tissues preferentially use different shuttles: heart, liver, and kidney use the more efficient malate-aspartate shuttle, while skeletal muscle and brain use the faster glycerol-3-phosphate shuttle.

VII. Shuttle Systems for Cytoplasmic NADH

The inner mitochondrial membrane is impermeable to NADH. Since glycolysis occurs in the cytoplasm and produces NADH there, cells need mechanisms to transfer the reducing equivalents (but not the NADH itself) into mitochondria for oxidation. Two shuttle systems accomplish this.

Malate-Aspartate Shuttle

This shuttle, found predominantly in heart, liver, and kidney, effectively transfers cytoplasmic NADH's electrons to mitochondrial NAD⁺, generating mitochondrial NADH that yields 2.5 ATP.

The mechanism involves a clever exchange of metabolites. Cytoplasmic NADH reduces oxaloacetate to malate (via cytoplasmic malate dehydrogenase). Malate crosses the inner membrane via a specific transporter and is reoxidized to oxaloacetate in the matrix (via mitochondrial malate dehydrogenase), generating mitochondrial NADH. The oxaloacetate cannot directly cross back to the cytoplasm; instead, it is transaminated to aspartate, which crosses to the cytoplasm and is transaminated back to oxaloacetate, completing the cycle.

Glycerol-3-Phosphate Shuttle

This shuttle operates in skeletal muscle and brain. It is faster but less efficient because electrons ultimately reduce FAD rather than NAD⁺.

Cytoplasmic NADH reduces dihydroxyacetone phosphate (DHAP) to glycerol-3-phosphate (G3P) via cytoplasmic glycerol-3-phosphate dehydrogenase. G3P diffuses to the outer surface of the inner membrane, where a different glycerol-3-phosphate dehydrogenase (an integral membrane protein with FAD as its prosthetic group) oxidizes G3P back to DHAP, reducing FAD to FADH₂. The FADH₂ transfers its electrons directly to ubiquinone in the electron transport chain. DHAP returns to the cytoplasm to accept more electrons.

Because electrons enter the chain at ubiquinone rather than at Complex I, they bypass the proton-pumping of Complex I. The result is fewer protons pumped and only 1.5 ATP per cytoplasmic NADH—a sacrifice of efficiency for speed.

<image>Panel A: Malate-aspartate shuttle with cytoplasmic MDH reducing OAA to malate which crosses membrane via antiporter. Panel B: Matrix MDH oxidizing malate to OAA generating NADH (enters Complex I, 2.5 ATP) with aspartate returning via glutamate-aspartate antiporter; tissues: heart, liver, kidney. Panel C: Glycerol-3-phosphate shuttle with cytoplasmic G3P dehydrogenase reducing DHAP to G3P, membrane-bound enzyme transferring electrons to CoQ (1.5 ATP); tissues: muscle, brain. Panel D: Comparison box: malate-aspartate more efficient (2.5 ATP) slower; glycerol-3-phosphate less efficient (1.5 ATP) faster.</image>

VIII. Inhibitors and Uncouplers

Several classes of agents interfere with oxidative phosphorylation, and understanding their mechanisms illuminates the process itself while having clinical and toxicological importance.

Electron Transport Chain Inhibitors

These compounds block electron flow through the chain. Rotenone, a pesticide and piscicide (fish poison), and certain barbiturates inhibit Complex I. Antimycin A, an antibiotic, inhibits Complex III. The most acutely toxic inhibitors block Complex IV: cyanide (found in certain plants and used in chemical manufacturing), carbon monoxide (from incomplete combustion), and azide (a laboratory reagent).

When electron flow stops, proton pumping stops, the proton gradient dissipates, and ATP synthesis ceases. Cells rapidly deplete ATP and die. Tissues with high metabolic rates (brain, heart) are most vulnerable. Cyanide poisoning produces "cherry-red" skin because venous blood remains oxygenated—tissues cannot extract oxygen. Treatment involves hydroxocobalamin (vitamin B12a, which binds cyanide) or the combination of nitrites (which generate methemoglobin that binds cyanide) and thiosulfate (which converts cyanide to thiocyanate for excretion).

ATP Synthase Inhibitors

Oligomycin blocks the proton channel in F₀, preventing proton flux through ATP synthase. When ATP synthase is blocked but the electron transport chain continues, protons accumulate in the intermembrane space until the gradient becomes too steep for further pumping. The chain then stops, as it cannot pump protons against the large gradient. ATP synthesis halts despite an intact proton gradient—the energy is trapped and cannot be used.

Uncouplers

Uncoupling agents dissipate the proton gradient without passing through ATP synthase. These lipophilic weak acids shuttle protons across the inner membrane: picking up a proton in the acidic intermembrane space, diffusing across the membrane in their protonated form, releasing the proton in the more alkaline matrix, and returning in their anionic form.

With protons leaking across the membrane, the gradient is dissipated and cannot drive ATP synthesis. However, the electron transport chain continues running freely—indeed, it speeds up because there is no longer back-pressure from the proton gradient. The energy that would normally produce ATP is instead released as heat.

Examples include 2,4-dinitrophenol (DNP), once used as a diet pill because it increases metabolic rate but banned after causing hyperthermia deaths; FCCP (carbonyl cyanide-p-trifluoromethoxyphenylhydrazone), used as a research tool; and thermogenin (UCP1), a physiological uncoupling protein in brown adipose tissue discussed below.

<image>Panel A: Normal oxidative phosphorylation with ETC complexes pumping protons (blue arrows), protons flowing through ATP synthase (gold) producing ATP (green check). Panel B: ETC inhibition (cyanide) with red X blocking Complex IV, no electron flow, gradient dissipates, ATP stops, skull toxicity icon. Panel C: ATP synthase inhibition (oligomycin) with blocked synthase (red X), proton accumulation, gradient too large stopping electron flow. Panel D: Uncoupling (DNP, thermogenin) with orange circle carrying protons across membrane bypassing synthase, increased electron flow, heat release (red wavy lines, thermometer).</image>

IX. Reactive Oxygen Species (ROS)

The electron transport chain handles enormous electron flux, and inevitably some electrons "leak" to oxygen prematurely, producing partially reduced and highly reactive oxygen species. Approximately 1-2% of electrons are estimated to form ROS, primarily at Complexes I and III where the single-electron carriers can transfer an electron to O₂, generating superoxide (O₂⁻).

Types of Reactive Oxygen Species

Superoxide (O₂⁻), the primary product of electron leak, is converted by superoxide dismutase (SOD) to hydrogen peroxide (H₂O₂). Hydrogen peroxide, while less reactive than superoxide, can generate the extremely dangerous hydroxyl radical (OH•) in the presence of iron (Fenton reaction). Hydroxyl radicals react indiscriminately with DNA, proteins, and lipids, causing oxidative damage.

Defense Systems

Cells possess multiple defenses against ROS. Superoxide dismutase rapidly converts superoxide to hydrogen peroxide. Catalase and glutathione peroxidase then convert hydrogen peroxide to water. Non-enzymatic antioxidants including vitamins E and C, glutathione, and coenzyme Q also scavenge free radicals.

Clinical Significance

Oxidative stress—an imbalance between ROS production and antioxidant defenses—contributes to numerous pathological conditions. Aging itself may result partly from cumulative oxidative damage to mtDNA, proteins, and lipids. Neurodegenerative diseases (Parkinson's, Alzheimer's), ischemia-reperfusion injury (stroke, myocardial infarction), and atherosclerosis all involve oxidative damage. Mitochondria, as both the source of ROS and a target of oxidative damage, occupy a central position in these processes.

X. Clinical Correlations

Mitochondrial Diseases

Mutations affecting oxidative phosphorylation cause a spectrum of disorders collectively known as mitochondrial diseases. These can result from mutations in either mitochondrial DNA (which encodes 13 ETC subunits and the RNA machinery for their synthesis) or nuclear DNA (which encodes the remaining 70+ subunits and all assembly factors).

Because mitochondria are maternally inherited and cells contain multiple mitochondria with multiple copies of mtDNA, mitochondrial genetics is complex. Heteroplasmy—the coexistence of mutant and wild-type mtDNA—explains the variable expressivity of mitochondrial diseases. Tissues with high energy demands (brain, heart, skeletal muscle, retina) are most vulnerable.

MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) results from tRNA mutations that impair mitochondrial protein synthesis. MERRF (myoclonic epilepsy with ragged-red fibers) similarly results from tRNA mutations, with characteristic muscle pathology showing aggregated abnormal mitochondria. Leigh syndrome, discussed previously, can result from mutations in Complex I, Complex IV, or pyruvate dehydrogenase. Leber hereditary optic neuropathy, caused by Complex I mutations, produces sudden bilateral vision loss in young adults.

Brown Fat and Thermogenesis

Brown adipose tissue contains abundant mitochondria rich in UCP1 (uncoupling protein 1, or thermogenin). This physiological uncoupling protein allows proton leak across the inner membrane, generating heat instead of ATP. Brown fat is essential for non-shivering thermogenesis in newborns, who have limited ability to shiver and abundant brown fat around vital organs. Hibernating animals use brown fat to rewarm from torpor.

Recent discovery that adult humans retain metabolically active brown fat has generated interest in activating this tissue to increase energy expenditure and combat obesity. Cold exposure and certain hormones stimulate brown fat activity.

<image>Panel A: White adipose histology (large cells, single lipid droplet, peripheral nuclei) versus brown adipose (smaller cells, multiple droplets, abundant mitochondria, central nuclei). Panel B: PET scan showing brown fat depots in supraclavicular and paravertebral regions (red/yellow high activity) after cold exposure. Panel C: Mitochondrion with ETC complexes and UCP1 thermogenin (orange channel) providing alternative proton pathway bypassing ATP synthase. Panel D: Heat release (red wavy lines, thermometer) with UCP1 activation by fatty acids and inhibition by purine nucleotides noted.</image>

Summary

Oxidative phosphorylation couples electron transport to ATP synthesis at the inner mitochondrial membrane. The electron transport chain consists of four complexes (I-IV) that transfer electrons from NADH and FADH₂ to oxygen, reducing it to water. The energy released drives proton pumping from the matrix to the intermembrane space, creating an electrochemical gradient (proton-motive force). ATP synthase (Complex V) uses this gradient to synthesize ATP through a rotary binding-change mechanism. Complete glucose oxidation yields approximately 30-32 ATP, depending on which shuttle system transports cytoplasmic NADH equivalents into mitochondria. Electron transport chain inhibitors (rotenone, cyanide) block electron flow and stop ATP production. ATP synthase inhibitors (oligomycin) allow gradient formation but prevent its use. Uncouplers (DNP, thermogenin) dissipate the gradient as heat without ATP production. Reactive oxygen species, generated as byproducts of electron transport, contribute to oxidative damage and disease. Mitochondrial diseases affect tissues with high energy demands and can result from mutations in mitochondrial or nuclear DNA.

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown